Dr. David J. Crossen This is Me

Education

 View all 6 references Web References

1. 1. Emedsecurities: Investment Banking

   www.emedsecurities.com/aboutus - [Cached]

   Published on: 1/24/2004   Last Visited: 1/24/2004

   K. Frank Austen, M.D. | Bengt Samuelsson, M.D. | Sir John Vane, D.Sc., FRS | Nicolas G. Bazan, M.D., Ph.D. | Charles A. Dinarello, M.D. | Stephen M. Prescott, M.D. | Lanny J. Rosenwasser, M.D. | Daniel D. Von Hoff, M.D. | David K. Brophy, Ph.D. | Brad Barber, Ph.D. | Campbell R. Harvey, Ph.D. | Henry I. Miller, M.D. | David J. Crossen, Ph.D. | Marc J. Ostro, Ph.D. | Alex McPherson, M.D., Ph.D. | Ronald Meade | Antoine A. Noujaim, Ph.D. | Ariel Elia | Carlo Patrono, M.D. | Thierry Jean, Ph.D.
   ...
   David J. Crossen, Ph.D. Dr. Crossen currently serves as a consultant to DCF Capital, a $650 Million healthcare hedge fund. Previously, he was a biotech analyst and partner at Montgomery Securities after serving as the biotech analyst at UBS Securities. Dr. Crossen also served as the senior pharmaceutical analyst at Sanford C. Bernstein & Co., covering all of the major U.S. drug companies, where he was named a partner and rated as an All-American Analyst. In 1987, he joined a private biotech company, Cortech, Inc. as president and CEO, where he undertook several private financings and corporate partner transactions, and brought the company public in 1992, raising $32 million, and then $56 million in a secondary offering in 1993. Dr. Crossen has an extensive publication record in medical journals and publications including The New York Times, Emergency Medicine, Hospital Practice, and Medical World News. He also served as editor of a series of technical medical publications including Guidelines to Antibiotic Therapy, Guidelines to Metabolic Therapy and Guidelines to Inflammation Therapy, all targeted at medical professionals. Dr. Crossen completed a Ph.D. in English Literature from Columbia University in 1977 and a Bachelor of Arts degree from New York University.

2. 2. eMedsecurities: Investment Banking

   www.emedtrade.com/aboutus_advi - [Cached]

   Published on: 12/14/2002   Last Visited: 12/14/2002

   K. Frank Austen, M.D. | Bengt Samuelsson, M.D. | Sir John Vane, D.Sc., FRS | Nicolas G. Bazan, M.D., Ph.D. | Charles A. Dinarello, M.D. | Stephen M. Prescott, M.D. | Lanny J. Rosenwasser, M.D. | Daniel D. Von Hoff, M.D. | David K. Brophy, Ph.D. | Brad Barber, Ph.D. | Campbell R. Harvey, Ph.D. | Henry I. Miller, M.D. | David J. Crossen, Ph.D. | Marc J. Ostro, Ph.D. | Alex McPherson, M.D., Ph.D. | Ronald Meade | Antoine A. Noujaim, Ph.D. | Ariel Elia | Carlo Patrono, M.D. | Thierry Jean, Ph.D. | A.E. Barry Cohen | Jean-Claude Gonneau
   ...
   David J. Crossen, Ph.D. Dr. Crossen currently serves as a consultant to DCF Capital, a $650 Million healthcare hedge fund. Previously, he was a biotech analyst and partner at Montgomery Securities after serving as the biotech analyst at UBS Securities. Dr. Crossen also served as the senior pharmaceutical analyst at Sanford C. Bernstein & Co., covering all of the major U.S. drug companies, where he was named a partner and rated as an All-American Analyst. In 1987, he joined a private biotech company, Cortech, Inc. as president and CEO, where he undertook several private financings and corporate partner transactions, and brought the company public in 1992, raising $32 million, and then $56 million in a secondary offering in 1993. Dr. Crossen has an extensive publication record in medical journals and publications including The New York Times, Emergency Medicine, Hospital Practice, and Medical World News. He also served as editor of a series of technical medical publications including Guidelines to Antibiotic Therapy, Guidelines to Metabolic Therapy and Guidelines to Inflammation Therapy, all targeted at medical professionals. Dr. Crossen completed a Ph.D. in English Literature from Columbia University in 1977 and a Bachelor of Arts degree from New York University.

3. 3. eMedsecurities: Investment Banking

   www.genomesecurities.com/about - [Cached]

   Published on: 9/18/2002   Last Visited: 9/18/2002

   K. Frank Austen, M.D. | Bengt Samuelsson, M.D. | Sir John Vane, D.Sc., FRS | Nicolas G. Bazan, M.D., Ph.D. | Charles A. Dinarello, M.D. | Stephen M. Prescott, M.D. | Lanny J. Rosenwasser, M.D. | Daniel D. Von Hoff, M.D. | David K. Brophy, Ph.D. | Brad Barber, Ph.D. | Campbell R. Harvey, Ph.D. | Henry I. Miller, M.D. | David J. Crossen, Ph.D. | Marc J. Ostro, Ph.D. | Alex McPherson, M.D., Ph.D. | Ronald Meade | Antoine A. Noujaim, Ph.D. | Ariel Elia | Carlo Patrono, M.D. | Thierry Jean, Ph.D. | A.E. Barry Cohen | Jean-Claude Gonneau | Gerard P. Joyce
   ...
   David J. Crossen, Ph.D. Dr. Crossen currently serves as a consultant to DCF Capital, a $650 Million healthcare hedge fund. Previously, he was a biotech analyst and partner at Montgomery Securities after serving as the biotech analyst at UBS Securities. Dr. Crossen also served as the senior pharmaceutical analyst at Sanford C. Bernstein & Co., covering all of the major U.S. drug companies, where he was named a partner and rated as an All-American Analyst. In 1987, he joined a private biotech company, Cortech, Inc. as president and CEO, where he undertook several private financings and corporate partner transactions, and brought the company public in 1992, raising $32 million, and then $56 million in a secondary offering in 1993. Dr. Crossen has an extensive publication record in medical journals and publications including The New York Times, Emergency Medicine, Hospital Practice, and Medical World News. He also served as editor of a series of technical medical publications including Guidelines to Antibiotic Therapy, Guidelines to Metabolic Therapy and Guidelines to Inflammation Therapy, all targeted at medical professionals. Dr. Crossen completed a Ph.D. in English Literature from Columbia University in 1977 and a Bachelor of Arts degree from New York University.